Cart
sales@molnova.com
Teplinovivint
CAS No. 1428064-91-8
Teplinovivint( —— )
Catalog No. M23586 CAS No. 1428064-91-8
Teplinovivint is a potent wnt/β-catenin signaling pathway inhibitor. It has anti-inflammatory activity and has the potential for tendinopathy research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 150 | In Stock |
|
| 5MG | 136 | In Stock |
|
| 10MG | 219 | In Stock |
|
| 25MG | 372 | In Stock |
|
| 50MG | 498 | In Stock |
|
| 100MG | 686 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTeplinovivint
-
NoteResearch use only, not for human use.
-
Brief DescriptionTeplinovivint is a potent wnt/β-catenin signaling pathway inhibitor. It has anti-inflammatory activity and has the potential for tendinopathy research.
-
DescriptionTeplinovivint is a potent wnt/β-catenin signaling pathway inhibitor. It has anti-inflammatory activity and has the potential for tendinopathy research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayWnt/Notch/Hedgehog
-
TargetWnt/beta/catenin
-
Recptorwnt/β-catenin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1428064-91-8
-
Formula Weight442.51
-
Molecular FormulaC25H26N6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:83.33 mg/mL (188.31 mM; Need ultrasonic)
-
SMILESO=C(C1=NNC2=C1C=C(C3=CC(CN4CCCCC4)=CN=C3)C=C2)NC5=CC=C(OC)N=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Vishal DESHMUKH, et al. Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors. WO2018075858A1.
molnova catalog
related products
-
Wnt/β-catenin agonis...
Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and is an effective Wnt agonist.
-
FIDAS-3
FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.?
-
N-(3-Methoxybenzyl)-...
N-3-methoxylBenzyllinolenicamide induces osteogenic differentiation and subsequent bone formation of mesenchymal stem cells by activating the canonical Wnt/β-catenin signaling pathway that can be used for osteoporosis research.
